Relay Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Relay Therapeutics, Inc. reported a quarterly adjusted loss of 37 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -43 cents. The mean expectation of thirteen analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -43 cents to -34 cents per share.

• Reported revenue was zero​; analysts expected $235.00 thousand.

• Relay Therapeutics, Inc.'s reported EPS for the quarter was a loss of 37 cents​.

• The company reported a quarterly loss of $81.75 million.

• Relay Therapeutics, Inc. shares had fallen by 3.4% this quarter and gained 106.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Relay Therapeutics, Inc. is $26.00, about 32.9% above its last closing price of $17.44

This summary was machine generated from LSEG data November 4 at 10:44 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)